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Abstract
Most chronic liver diseases of all etiologies result in progressive liver fibrosis. Myofibroblasts produce the
extracellular matrix, including type I collagen, which constitutes the fibrous scar in liver fibrosis. Normal liver has
little type I collagen and no detectable myofibroblasts, but myofibroblasts appear early in experimental and clinical
liver injury. The origin of the myofibroblast in liver fibrosis is still unresolved. The possibilities include activation of
endogenous mesenchymal cells including fibroblasts and hepatic stellate cells, recruitment from the bone marrow,
and transformation of epithelial or endothelial cells to myofibroblasts. In fact, the origin of myofibroblasts may be
different for different types of chronic liver diseases, such as cholestatic liver disease or hepatotoxic liver disease.
This review will examine our current understanding of the liver myofibroblast.
Background
Myofibroblasts are alpha smooth muscle actin positive
cells that produce extracellular matrix proteins including
fibrillar collagen. Myofibroblasts are characterized immu-
nophenotypically by a spindle or stellate shape, pale eosi-
nophilic cytoplasm, expression of abundant pericellular
matrix and fibrotic genes (vimentin, a-smooth muscle
actin (a-SMA), non-muscle myosin, fibronectin, and col-
lagen Type I) [1,2]. Ultrastructurally, myofibroblasts are
defined by prominent rough endoplasmic reticulum, a
Golgi apparatus producing collagen, peripheral myofila-
ments, fibronexus (no lamina) and gap junctions [2]. In
liver fibrosis, the myofibroblasts are imbedded in the
fibrous scar. In both experimental and clinical liver fibro-
sis, there is a close correlation between the regression of
liver fibrosis and the disappearance of these myofibro-
blasts. There is general agreement that these myofibro-
blasts are the source of the excessive extracellular matrix
proteins in liver fibrosis. Therefore, identifying the origin
of these myofibroblasts will provide insight into the
pathology of liver fibrosis and perhaps into new therapeu-
tic targets.
There are at least three potential sources of myofibro-
blasts in the liver (see Figure 1). The resident mesenchymal
cells, consisting of the quiescent hepatic stellate cell and the
tissue fibroblasts, can potentially become myofibroblasts.
These cells are characterized by CD45-, CD34-, desmin+,
glial fibrillar associated protein (GFAP)+, and thy-1+.
Recent studies have proposed hepatocytes, cholangiocytes,
and endothelial cells can become myofibroblast through
epithelial or endothelial mesenchymal transition (EMT).
These cells include CD45-, albumin+ (i.e. hepatocytes),
CD45-, CK19+ (i.e. cholangiocytes), or Tie2+ (endothelial
cells). Finally, bone-marrow derived cells, consisting of
fibrocytes and circulating mesenchymal cells, can be
recruited to the injured liver to become myofibroblasts.
These cells are CD45+ (fibrocytes), CD45+/- (circulating
mesenchymal cells), collagen type I +, CD11d+, and MHC
class II+.
The assessment of the cell fate of cells in vivo in mice
has been greatly facilitated by the generation of transgenic
mice that either express a reporter gene or express the
recombinase cre under a cell-specific promoter to perma-
nently label a cell and its progeny. We have utilized the
collagen alpha1(I) GFP mouse in which the green fluores-
cent protein (GFP) is expressed under control of the col-
lagen alpha1(I) promoter/enhancer [3]. These mice can
then undergo chronic liver injury such as bile-duct ligation
or carbon tetrachloride treatment to induce liver fibrosis
and their myofibroblasts will express the GFP so are easily
identified by their green fluorescence. * Correspondence: dbrenner@ucsd.edu
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fibrocytes to the myofibroblast population in chronic liver
injury. Fibrocytes are a unique population of type I col-
lagen expressing CD45+ cells derived from the bone mar-
row. Fibrocytes are defined as spindle shaped “CD45 and
collagen type I (Col
+) expressing leukocytes that mediate
tissue repair and are capable of antigen presentation to
naive T cells” [4]. Due to their ability to differentiate into
myofibroblasts in culture, fibrocytes are implicated in the
fibrogenesis of skin, lungs, kidneys, and liver [5,6]. In addi-
tion to collagen Type I, fibronectin and vimentin, fibro-
cytes express CD45, CD34, MHCII, MHCI, CD11b, Gr-1,
and secrete growth factors (transforming growth factor
(TGF)-b1, monocyte chemotactic factor (MCP)-1) that
promote deposition of extracelluar matrix proteins [7].
Upon injury or stress, fibrocytes proliferate and migrate to
the injured organ [5,7,8]. The number of recruited fibro-
cytes has been reported to vary from 25% in lung fibrosis
[9,10] to ≈3-5% in liver fibrosis (e.g. BDL and CCl4) [11] of
the collagen expressing cells, suggesting that the magni-
tude of fibrocyte differentiation into myofibroblasts
depends on the organ and the type of injury. Interestingly,
human serum amyloid protein (hSAP), which inhibits the
differentiation of monocytes into fibrocytes, has been
shown to inhibit fibrosis in lungs, kidneys and the liver
[12-14]. This suggests that fibrocytes may have a role in
fibrosis that is greater than their quantitative contribution
to the myofibroblast population. In particular, fibrocytes
support innate and adaptive immune responses [15].
To assess the potential contribution of fibrocytes in
liver fibrosis, the Coll-GFP mice were used as donors in
bone marrow transplantation into wild-type recipient
mice. After recovery from the transplantation, these mice
underwent live injury by CCl4 or BDL. In this way any
GFP+ (i.e. collagen Type I expressing) cell found in the
liver had to be derived from the bone marrow. This study
demonstrated the approximately 5% of collagen Type I
expressing cells in the injured liver were from the bone
marrow. In particular, these cells fulfilled the definition
of the fibrocytes in that they were GFP+ (expressing col-
lagen Type I) and CD45+. Additional immunohistochem-
istry studies confirmed that these cells were expressing
the collage Type I protein [11,16].
Next, the role of EMT was assessed using cell type spe-
cific CRE transgenic mice crossed with floxed ROSA26
beta galactosidase reporter gene mice. To assess the role
of hepatocytes undergoing EMT into myofibroblasts, the
albumin CRE reporter mice were used. Interestingly,
Figure 1 Origin of myofibroblasts.
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cytes changed their confirmation to appear more
fibroblast like and started expressing the collagen Type I.
Therefore, it appeared that hepatocytes can undergo
EMT in primary cultures. However, when these reporter
mice underwent CCl4 induced liver fibrosis, the results
were completely different. In vivo,t h e r ew a ss t r o n g
expression of Coll-GFP reporter in pericentral zones of
the liver with bridging fibrosis as expected. However,
none of the GFP+ myofibroblasts also expressed beta
galactosidase [17]. Purification of the non-parenchymal
cells from the injured liver confirmed that none of the
collagen type 1 expressing cells were previously hepato-
cytes i.e. were expressing the ROSA26 beta galactosidase
reporter. Thus, in vivo, there is no evidence that collagen
producing cells (myofibroblasts) originate from hepato-
cytes in CCl4 induced liver fibrosis in mice [17].
Assessing the potential role of cholangiocytes to
undergo EMT required an inducible CK19 CRE transgenic
mouse. This is because CK19 is expressed in many epithe-
lial cells during development, but only in cholangiocytes in
the liver in the adult mouse. As predicted, the inducible
CK19 specifically was expressed in cholangiocytes in the
liver in the adult mouse. When compared to markers of
myofibroblasts, there was no overlap between the expres-
sion of the CK19 YFP reporter and immune-fluorescence
for alpha smooth muscle actin, FSP1, or desmin [18].
FSP1 (also called S100A4) is expressed in fibroblasts
and has been proposed as a marker of EMT. FSP1 is
strongly expressed in the injured liver. Surprisingly, it
does not co-expressed in cells with markers of the
mesenchymal phenotype, such as type 1 collagen or
alpha smooth muscle actin. Therefore, we investigated
which cells were actually expressing FSP1 in the injured
liver. In culture, FSP1 was strongly expressed in fibro-
blasts derived from mouse ears as expected. However, it
was not expressed in activated hepatic stellate cells in
culture. Instead, the FSP1+ cells from the injured liver
purified in the Kuffer cells/macrophage fraction of the
non-parenchymal hepatic cells. By fluorescent sorting for
FSP1+ cells using an FSP1-GFP reporter mouse, we were
able to purify to homogeneity these FSP1+ cells. These
cells then underwent gene expression microarray analysis
a n dt h e nc o m p a r e dt oa l la v a i l a b l eg e n ee x p r e s s i o n
microarrays. An ontology analysis revealed that these
FSP1+ cells were closest in resembling activated macro-
phage and bone marrow derived dendritic cells. A subse-
quent ontology analysis showed that FSP1+ cells closely
resembled activated macrophage [19]. The function of
these cells in the injured liver is unknown.
Fibroblasts are primarily located in the portal tract in the
normal liver. Recent studies [20] had demonstrated that
thy-1 is a potential marker of activated myofibroblasts in
the injured liver. This study demonstrated an overlap in
experimental fibrosis between thy-1 and alpha smooth
muscle actin, implying that some myofibroblasts are
derived from fibroblasts in liver fibrosis. Studies from
other researchers have proposed that TE-7, an antibody
against elastin, specifically identifies fibroblasts in the liver
[21,22].
Several markers have been proposed to be specific for
hepatic stellate cells, whether in the quiescent or acti-
vated state. These include the florescence of Vitamin A
in the lipid droplets, GFAP, p75 NGF receptor, and
synaptophysin [23-26]. Using these markers one should
be able to distinguish between myofibroblasts that origi-
nate from fibroblasts or from hepatic stellate cells in
experimental liver fibrosis.
From our studies and the published studies from other
laboratories, we have concluded that in experimental mod-
els of liver fibrosis, most fibrogentic cells (myofibroblasts)
are endogenous to the liver. It appears that the activated
hepatic stellate cells and fibroblasts are the major endo-
genous fibrogenic cells, and that now these two cell types
can be distinguished in vivo. On the other hand, fibrocytes
migrate from the bone marrow to the liver where they
contribute to inflammation and fibrosis, but are a minor
component of the liver myofibroblast population. In some
model systems and in patients with primary sclerosing
cholangitis, there is evidence for EMT of the injured cho-
lagiocytes on the basis of the co-expression of mesenchy-
mal and epithelial markers, but no one has reported any
clear evidence of epithelial cells becoming myofibroblasts.
FSP1 (S100A4) identifies a myelomonocytic cell and not a
fibroblast or myofibroblast in fibrotic mouse liver. Using
genetic cell fate mapping, neither cholangiocytes nor hepa-
tocytes transform into fibrogentic cells (myofibroblasts) in
mouse models of liver fibrosis.
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